Bvf Inc/il
About Bvf Inc/il’s 13F portfolio
Bvf Inc/il is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Bvf Inc/il reported $3.9B across 44 US-listed positions (). Its largest position is REVOLUTION MEDICINES INC (RVMD) at 14% of the reported book, and its ten biggest holdings make up 66% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.82 −1.76% | 14% | 3.0M | $555.3M |
| 2 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | $121.13 −0.32% | 11% | 3.9M | $444.0M |
| 3 | NASDAQ: XOMA XOMA ROYALTY CORPORATION | $40.17 0.00% | 8.3% | 7.6M | $322.7M |
| 4 | NASDAQ: MLTX MOONLAKE IMMUNOTHERAPEUTICS | $10.79 −4.09% | 8.0% | 16.0M | $311.5M |
| 5 | NASDAQ: GHRS GH RESEARCH PLC | $18.25 −0.11% | 5.9% | 8.7M | $232.5M |
| 6 | NASDAQ: GPCR STRUCTURE THERAPEUTICS INC | $17.36 −4.46% | 4.6% | 3.4M | $180.7M |
| 7 | NASDAQ: NKTR NEKTAR THERAPEUTICS | $34.42 −4.15% | 4.3% | 2.4M | $166.9M |
| 8 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | $92.49 +0.59% | 3.2% | 1.1M | $123.6M |
| 9 | NASDAQ: XNCR XENCOR INC | $34.39 −0.32% | 2.9% | 7.1M | $114.9M |
| 10 | NASDAQ: ALKS ALKERMES PLC | $46.85 +3.08% | 2.9% | 2.2M | $112.9M |
| 11 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | $9.07 0.00% | 2.8% | 4.5M | $108.0M |
| 12 | NASDAQ: CGEM CULLINAN THERAPEUTICS INC | $9.01 −2.86% | 2.7% | 5.8M | $104.7M |
| 13 | NASDAQ: PVLA PALVELLA THERAPEUTICS INC NE | $146.58 +1.54% | 2.6% | 673K | $102.8M |
| 14 | NASDAQ: ZYME ZYMEWORKS INC | $26.04 +0.77% | 2.4% | 3.6M | $95.4M |
| 15 | NASDAQ: KURA KURA ONCOLOGY INC | $7.34 −2.00% | 2.4% | 8.4M | $92.7M |
| 16 | NASDAQ: IRON DISC MEDICINE INC | $77.98 +1.84% | 2.2% | 1.2M | $84.4M |
| 17 | NASDAQ: STOK STOKE THERAPEUTICS INC | $26.69 +1.06% | 2.1% | 2.5M | $83.4M |
| 18 | NASDAQ: OLMA OLEMA PHARMACEUTICALS INC | $7.06 −2.22% | 1.7% | 5.3M | $66.3M |
| 19 | NASDAQ: ANNX ANNEXON INC | $3.52 +1.44% | 1.3% | 8.7M | $49.7M |
| 20 | NASDAQ: CBIO CRESCENT BIOPHARMA INC. | $12.40 −4.91% | 1.3% | 2.7M | $49.5M |
| 21 | NASDAQ: ACIU AC IMMUNE SA | $2.10 −0.47% | 1.2% | 19.8M | $47.2M |
| 22 | NASDAQ: TYRA TYRA BIOSCIENCES INC | $19.61 +0.20% | 1.2% | 1.5M | $47.1M |
| 23 | NASDAQ: STRO SUTRO BIOPHARMA INC | $8.50 −4.71% | 1.1% | 1.3M | $41.6M |
| 24 | NASDAQ: IMCR IMMUNOCORE HLDGS PLC | $27.51 −1.08% | 1.1% | 1.3M | $41.1M |
| 25 | NASDAQ: AVTX AVALO THERAPEUTICS INC | $6.70 −6.03% | 1.0% | 2.1M | $38.4M |
Showing 1–25 of 44 positions on this page reported in this 13F.
- Healthcare100%
- AddedRVMDREVOLUTION MEDICINES INC+3.8%$555.3M
- AddedXOMAXOMA ROYALTY CORPORATION+193%$322.7M
- AddedALKSALKERMES PLC+7.7%$112.9M
- AddedAVTXAVALO THERAPEUTICS INC+27.1%$38.4M
- NewQTTBQ32 BIO INC—$29.9M
- NewABSIABSCI CORPORATION—$27.4M
- AddedIVVDINVIVYD INC+44.3%$24.6M
- NewSGMTSAGIMET BIOSCIENCES INC—$19.3M
- AddedOKURONKURE THERAPEUTICS INC+63.5%$14.8M
- NewIMUXIMMUNIC INC—$11.8M
- ReducedKYMRKYMERA THERAPEUTICS INC−29.6%$444.0M
- ReducedGPCRSTRUCTURE THERAPEUTICS INC−2.7%$180.7M
- ReducedNKTRNEKTAR THERAPEUTICS−6.6%$166.9M
- ReducedMIRMMIRUM PHARMACEUTICALS INC−33.4%$123.6M
- ReducedPVLAPALVELLA THERAPEUTICS INC NE−30.0%$102.8M
- ReducedZYMEZYMEWORKS INC−2.3%$95.4M
- ReducedIRONDISC MEDICINE INC−9.3%$84.4M
- ReducedTYRATYRA BIOSCIENCES INC−25.3%$47.1M
- SoldCMPXCOMPASS THERAPEUTICS INC−100%—
- SoldENGNWENGENE HOLDINGS INC−100%—
Reading Bvf Inc/il’s 13F portfolio
Bvf Inc/il’s $3.9B 13F book is spread across 44 reported positions and is highly concentrated — its ten largest positions alone are 66% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RVMD, KYMR, XOMA, MLTX and GHRS, led by REVOLUTION MEDICINES INC (RVMD) at 14% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Bvf Inc/il changed last quarter
Between 2026-03-31 and Q2 2026, Bvf Inc/il was roughly balanced between buying and selling: it opened 7 new positions and added to 6 more, while trimming 8 and closing 4 outright. Against a 44-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was REVOLUTION MEDICINES INC (RVMD), and its biggest reduction was KYMERA THERAPEUTICS INC (KYMR).
What a 13F does and doesn’t reveal
A 13F captures only Bvf Inc/il’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Bvf Inc/il is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Bvf Inc/il's profile on this page is built directly from those filings.
How current is the 13F data on Bvf Inc/il's page?
It reflects Bvf Inc/il's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Bvf Inc/il files its next quarterly report, this page refreshes automatically.
Can I see Bvf Inc/il's complete list of holdings?
This page highlights Bvf Inc/il's largest positions rather than all 44 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Bvf Inc/il's filings.
Does a 13F show everything Bvf Inc/il owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Bvf Inc/il's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Bvf Inc/il made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

